Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here.

 
You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile.
Pharmaceutical Executive Europe E-News
 
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecdigi
 
Survey
We asked 40 pharma leaders for their thoughts on what the pharma marketing landscape might look like in 2017...

US DTC will be banned 3%
Traditional sales reps will be extinct 26%
Global sales of drugs will increase 26%
Drugs will will more efficiently targets 45%

Talk to us:
editor@pharmexeceurope.com

Advertise with us: jgray@advanstar.com

28 February, 2012
In this Issue
AZ's Real-World Evidence Gamble
Will AstraZeneca's recently announced real-world evidence collaboration with IMS Health be successful in proving that all-important word: value? More...
Pharma Worst Hit by 'Talent Challenge'
A recent global CEO report reveals that pharma CEOs outweigh those from other industries in thinking it has become more difficult to hire workers. More...
2012: A Dramatic Year for Servier
Whichever way you look at it, 2012 will be a dramatic year for Servier. The French company has a number of collaborations that could lead to a new generation of products, but any positive news from these developments is likely to be overshadowed by the ongoing scandal of its diabetes treatment, Mediator. More...
Clinical Trials: The 'Big Data' Era
Vendors may have developed systems for massive databases, but are we data ready, asks Wayne R. Kubick. More...
Also in this issue…
Biomanufacturing Outlook 2012
FDA Issues Warning Letters to Merck KGaA Plants
Europe's Economic Crisis: The Effect on Outsourcing to Emerging Markets
Case Study
Reducing outsourcing costs and cycle-times
Discover how a biotech saved $600,000 on a Phase II contract, compressed the contracting cycle-time from three months to two weeks, and formed a more constructive and collaborative working relationship with their CRO.
Download the case study today.
Event Profile
Pharma Regulatory Policy Exchange
May 7-8, 2012
Washington, D.C.
USA
Prepare for a new wave of legislative and regulatory policies that will shape the life sciences industry for years to come. Learn best practices on how the shifting regulatory and policy landscape will affect the biopharma industry going forward with Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Eisai, Eli Lilly and Company, EMD Serono, Merck, Novartis and Shire Pharmaceuticals!
Register by March 10th at http://www.cbinet.com/policyexchange and save $300 with priority code: QSS925.

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone
numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other
opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact
information available to third parties for marketing purposes, please contact us by emailing magazines@superfill.com or by mail
at Advanstar Communications Inc., Bridgegate Pavilion, 4A Chester Business Park, Wrexham Road, Chester, CH4 9QH, UK